Basket | Login | Register


Current projects

Our work

All projects Alzheimer Europe is currently involved in are listed here. News about these projects, can be found here.

AE: 2019 Ethical issues

Thanks to funding from the European Commission operating grant, in 2019 Alzheimer Europe will explore the ethical issues which may arise in the process of involving people with dementia in research. We will identify and address issues related to the involvement of people with dementia as research participants as well as in the context of Public and Patient Involvement (PPI). A working group will be set up, a literature review conducted and a report produced. This will also be an opportunity to explore an additional issue of relevance to minority ethnic groups (which was the topic of last year's work which was funded partly by our operating grant from the European Commission and partly by the Robert Bosch Stiftung), namely their under-involvement in dementia research. In 2019, work will also continue on the development of the database of initiatives and materials for intercultural care and support, and one or more articles are planned, which will hopefully be published in the course of the year.

AE: Dementia in Europe Yearbook 2018

In 2018, AE will continue to work on making dementia a European priority and supporting the development of dementia strategies. This year, AE will collect information on existing national dementia strategies in Europe. The 2018 Yearbook will compare and analyse the main commonalities and differences regarding the topics addressed in the strategies, as well as other key aspects such as funding, implementation and evaluation of the strategies. This will lead to the publication of national reports, a comparative report and the identification of best practices in this field.

AE: Clinical Trial Watch (CTW)

In September 2016, AE announced the launch of the CTW - a service bringing together accessible and up-to-date information on clinical trials that are investigating drugs for the treatment and prevention of Alzheimer’s disease and/or dementia. At a first stage of the project, only clinical trials in phase III and that are currently recruiting participants in at least one European country are included in the CTW. Alzheimer Europe and its EWGPWD have designed and developed the contents of the summary reports that are included in the CTW. The sponsors of the clinical trials have also been consulted on the information contained on the reports.
 The current database provides information on phase II and phase III clinical trials for Alzheimer’s disease and/or dementia. In 2019, AE will continue updating this innovative resource by including phase II and phase III clinical trials being conducted in Europe.

PACE (2014-2019)

The PACE project aims to describe and compare the effectiveness of healthcare systems in six European countries with (Belgium, Netherlands, UK) and without (Finland, Italy, Poland) formal palliative care structures for long-term care facilities in terms of patient and family outcomes, quality of palliative care and cost-effectiveness, and in terms of staff knowledge, practices and attitudes. This involves mapping palliative care systems across Europe, a retrospective, representative cross-sectional study of deaths in long-term care facilities in each of the six participating countries and an interventional study measuring the impact of training on the quality of the end-of-life experience.

AETIONOMY (2014-2019)

AETIONOMY is a five-year project that began in February 2014. It aims to identify subgroups of dementia and Parkinson’s disease - based on the underlying genetic or molecular causes of the variants - in order to allow tailored therapies. The project will involve the collection of clinical data, imaging and genetic data and will create a new way to combine all of these together to look for patterns which could identify sub-groups of patients with similar causes of their disease.

EPAD (2015-2019)

The European Prevention of Alzheimer’s dementia (EPAD) initiative is a collaborative research effort to improve the chance of successfully preventing Alzheimer’s dementia and to better understand early aspects of Alzheimer’s disease before dementia develops. The goal of the initiative is the prevention of dementia in people with evidence of the disease (such as biomarker abnormalities) who still may have little or no complaints or clinical symptoms. EPAD will establish a European-wide cohort of over 6,000 participants, of which 1,500 will be invited to participate in a trial to test new treatments for the prevention of Alzheimer’s dementia. The five year programme is part of the Innovative Medicines Initiative, a joint undertaking between the European Union and the European Federation of Pharmaceutical Industries and Associations, EFPIA.

SyDAD (2015-2019)

SyDAD (Synaptic Dysfunction in Alzheimer's Disease) is a European Training Network, sponsored by Horizon 2020 Marie Sklodowska Curie Actions. The research programme will focus on synaptic dysfunction, the main connection point between pathology and cognitive decline in Alzheimer’s disease. It will support and train 15 Early Stage Researchers (ESRs, PhD students) with an interest in the area of Alzheimer’s disease and synaptic dysfunction, focusing on new drugs and biomarkers. The project is led by the Department of Neurobiology, Care Sciences and Society at Karolinska Institutet (Sweden).

INDUCT (2016-2019)

INDUCT (Interdisciplinary Network for Dementia Utilising Current Technology) is a four year project under the Marie Sklodowska-Curie Actions Programme. The main aim of INDUCT is to develop a premier quality multi-disciplinary, multi-professional and intersectorial education and training research framework for Europe aimed at improving technology and care for people with dementia, and to use the coherent themes and interrelated Early Stage Researchers ESRs within INDUCT to provide the evidence to show how technology can improve the lives of people with dementia.

MinD (2016-2019)

MinD (Designing for People with Dementia) is a four year project under the Marie Sklodowska-Curie Actions Programme. It aims to help people with dementia engage in social contexts to improve psychosocial wellbeing. Design can offer novel ways of complementing existing care approaches to empower people with dementia in everyday social situations. The project partners will use the concept of mindful design to investigate innovative design solutions, in order to enable self-empowerment and confidence building of people living with dementia. There will be two focus areas: a) personal difficulties with social interaction and b) environmental influences on social engagement. In these two contexts, we will study how personal, wearable designs can help mediate perceptions of identity and emotion management; and how environmental aspects can reduce feelings of information overload and instill feelings of self-empowerment and control.

AMYPAD (2016-2021)

The "Amyloid imaging to prevent Alzheimer’s disease" project aims to improve the diagnostic workup of patients suspected to have Alzheimer's disease and their management. The partners aim to improve knowledge of the natural history of AD in a pre-symptomatic stage, in order to better select patients for trials. In addition, they will monitor changes in beta amyloid deposition in the brain, in order to quantify the impact of novel therapies.

DEM 2 - 2nd European Joint Action on Dementia (2016-2019)

The aim of the 2nd European Joint Action on Dementia, known as Dementia Two or DEM 2, is to promote the implementation in EU Member States of coordinated actions to improve the situation of people living with dementia and their carers. These actions were identified by ALCOVE, the first European Joint Action on Alzheimer Cooperative Valuation in Europe, whose partners built a wealth of evidence and knowledge to support Member States in developing their dementia policies and operational capacity. DEM 2 will focus on four key areas for action: diagnosis and post diagnostic support, crisis and care coordination, residential care and dementia-friendly communities.

ROADMAP (2016-2018)

The "Real World Outcomes across the Alzheimer’s Disease spectrum for better care: Multi-modal data Access Platform" project provides the foundation for an integrated data environment and framework for real-world evidence (RWE) in Alzheimer's disease. This includes the development of consensual key outcome measures and data integration tools for dataset characterisation and outcome classification, as well as guidelines on the handling and interpretation of RWE data. ROADMAP has a budget of EUR 8.21 million and 26 partners led by the University of Oxford and Novartis.

MOPEAD (2016-2019)

This 33-month project aims to deliver a step-change in Alzheimer’s disease (AD) patient engagement strategies and a paradigm shift from late-stage diagnosis to early-stage diagnosis. Multiple regional project sites will be established to identify and test models of efficient early identification of mild AD dementia and prodromal AD patients. These models will be compared and contrasted to identify ways to improve early detection and diagnosis of AD. The findings will enable models of patient access to be established and used in the broader AD community. The four patient engagement models which will be tested in five countries (Germany, Netherlands, Slovenia, Spain and Sweden) include assessment based on AD citizen science (online), Open House Initiatives, Primary care and diabetologists’ offices. MOPEAD is mainly sponsored by the European Union’s Horizon 2020 research and innovation programme and the European pharmaceutical industry (via EFPIA) under the auspices of the Innovative Medicines Initiative (IMI) 2 Joint Undertaking.

PRODEMOS (2018-2023)

The PRODEMOS (Prevention of Dementia using Mobile phone Applications) kicked off in January 2018 and will run for five years. This project aims to make an evidence-based dementia prevention strategy using mobile Health accessible to those at increased risk of dementia who are usually not reached by preventive medicine. From a global perspective, the project will target socio-economically deprived populations in the EU and a population at risk of dementia in China. The final aim is to implement this flexible, fully adaptable mHealth platform in a culturally appropriate form in a range of health care settings across the globe. The PRODEMOS project is led by Eric Moll van Charante and Edo Richard (Academish Medisch Centrum bij de Universiteit van Amsterdam). It is sponsored by the European Union’s Horizon 2020 research and innovation programme.

PARADIGM (2018-2020)

PARADIGM - Patients Active in Research and Dialogues for an Improved Generation of Medicines - is an IMI-funded European project with a mission to provide a unique framework that enables structured, effective, meaningful, ethical, innovative, and sustainable patient engagement (PE) and demonstrates the “return on the engagement” for all players. The objective is to develop much needed processes and tools for three key decision-making points: research priority setting, design of clinical trials and early dialogue. Building on advances at international level, PARADIGM will integrate the needs, perspectives and expectations of all actors (including vulnerable populations) involved and will also produce a set of metrics to measure the impact of patient engagement. PARADIGM began on 1 March 2018, for 30 months. Alzheimer Europe is a partner and is involved in all work packages of this project.

NEURONET (2019-2022)

The NEURONET initiative (Efficiently Networking European Neurodegeneration Research) is a three-year coordination and support action that began in March 2019. Its aim is set up an efficient platform to boost synergy and collaboration across the Innovative Medicines Initiative (IMI) projects of the Neurodegenerative Disorders (ND) portfolio, assisting in identifying gaps, multiplying its impact, enhancing its visibility and facilitating dovetailing with related initiatives in Europe and worldwide.



Last Updated: Tuesday 23 April 2019